Search

Your search keyword '"Palmieri, Fabrizio"' showing total 428 results

Search Constraints

Start Over You searched for: Author "Palmieri, Fabrizio" Remove constraint Author: "Palmieri, Fabrizio" Publication Year Range Last 50 years Remove constraint Publication Year Range: Last 50 years
428 results on '"Palmieri, Fabrizio"'

Search Results

6. Sarilumab plus standard of care vs standard of care for the treatment of severe COVID-19: a phase 3, randomized, open-labeled, multi-center study (ESCAPE study)

7. Epidemiology of ventilator-associated pneumonia in ICU COVID-19 patients: an alarming high rate of multidrug-resistant bacteria

8. Proteomic analysis identifies a signature of disease severity in the plasma of COVID-19 pneumonia patients associated to neutrophil, platelet and complement activation

9. Accuracy of QuantiFERON SARS-CoV-2 research use only assay and characterization of the CD4+ and CD8+ T cell-SARS-CoV-2 response: comparison with a homemade interferon-γ release assay

12. Implementation of Whole Genome Sequencing of Tuberculosis Isolates in a Referral Center in Rome: Six Years’ Experience in Characterizing Drug-Resistant TB and Disease Transmission

13. Utility of Liver Biopsy in the Diagnosis and Management of Possible Drug-Induced Liver Injury in Patients Receiving Antituberculosis Therapy: A Retrospective Study

14. Diagnosis of Tuberculosis in a Case of Chronic Urticaria following Omalizumab Therapy

16. Role of testosterone in SARS-CoV-2 infection: A key pathogenic factor and a biomarker for severe pneumonia

17. Risk and predictive factors of prolonged viral RNA shedding in upper respiratory specimens in a large cohort of COVID-19 patients admitted to an Italian reference hospital

18. Worldwide Effects of Coronavirus Disease Pandemic on Tuberculosis Services, January-April 2020

21. A randomized trial of pamrevlumab in patients with COVID‐19 pneumonia

24. Evolution of SARS‐CoV‐2 variants of concern over a period of Delta and Omicron cocirculation, among patients hospitalized for COVID‐19 in an Italian reference hospital: Impact on clinical outcomes

27. Early expansion of myeloid-derived suppressor cells inhibits SARS-CoV-2 specific T-cell response and may predict fatal COVID-19 outcome

28. Infection control, genetic assessment of drug resistance and drug susceptibility testing in the current management of multidrug/extensively-resistant tuberculosis (M/XDR-TB) in Europe: A tuberculosis network European Trialsgroup (TBNET) study

29. Sarilumab plus standard of care vs standard of care for the treatment of severe COVID-19: a phase 3, randomized, open-labeled, multi-center study (ESCAPE study)

30. Characterization of the immune impairment of tuberculosis and COVID-19 coinfected patients

33. A whole blood test to measure SARS-CoV-2-specific response in COVID-19 patients

35. Effectiveness and Safety of Imipenem-Clavulanate Added to an Optimized Background Regimen (OBR) Versus OBR Control Regimens in the Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis

37. Identification of HLA-E Binding Mycobacterium tuberculosis–Derived Epitopes through Improved Prediction Models

38. Evaluation of the immunomodulatory effects of interleukin-10 on peripheral blood immune cells of COVID-19 patients: Implication for COVID-19 therapy

39. Coordinated innate and T-cell immune responses in mild COVID-19 patients from household contacts of COVID-19 cases during the first pandemic wave

41. Co-administration of treatment for rifampicin-resistant TB and chronic HCV infection: A TBnet and ESGMYC study

42. Humoral and Cellular Response to Spike of Delta SARS-CoV-2 Variant in Vaccinated Patients With Multiple Sclerosis

43. Timing and outcomes of noninvasive ventilation in 307 ARDS COVID-19 patients: an observational study in an Italian third level COVID-19 hospital

44. Impact of Vitamin D in Prophylaxis and Treatment in Tuberculosis Patients

45. Characteristics and Outcomes of COVID-19-Related Hospitalization among PLWH

46. Co-administration of treatment for rifampicin-resistant TB and chronic HCV infection: A TBnet and ESGMYC study

47. Additional file 1 of Proteomic analysis identifies a signature of disease severity in the plasma of COVID-19 pneumonia patients associated to neutrophil, platelet and complement activation

48. Sarilumab Plus Standard of Care Versus Standard of Care for the Treatment of Severe COVID-19: A Phase 3, Randomized, Open-Labeled, Multi-Center Study (ESCAPE Study)

49. Potential Role of Vitamins A, B, C, D and E in TB Treatment and Prevention: A Narrative Review

50. B3 Lesions at Vacuum-Assisted Breast Biopsy under Ultrasound or Mammography Guidance: A Single-Center Experience on 3634 Consecutive Biopsies

Catalog

Books, media, physical & digital resources